【摘要】 目的　探讨多药耐药基因mdr 1及其蛋白P gp、凋亡抑制基因bcl 2及其相关蛋白P2 6 bcl 2在中、高度恶性非霍奇金淋巴瘤 (NHL)患者中表达的临床意义及潜在的预后价值。方法　应用免疫组织化学S P法对 6 0例NHL患者进行检测。结果　 6 0例患者中P gp表达阳性者 15例 ,P2 6 bcl 2表达阳性者 2 5例。P gp和P2 6 bcl 2共同表达为阴性者的 3年生存率明显高于阳性表达者 (分别为48 48%和 15 .38% ,P =0 .0 38)。结论　P gp、P2 6 bcl 2表达与中、高度恶性NHL患者的化疗效果及预后相关。P gp和P2 6 bcl 2共同表达情况可作为预测中、高度恶性NHL患者化疗敏感性及预后的指标 ,对指导临床治疗具有意义更多还原

【Abstract】 Objective To investigate the relationship between the expression of P gp, P26 bcl 2 and the prognosis in intermediate and high grade non Hodgkin’s lymphomas(NHL). Methods Sixty cases of intermediate and high grade NHL were retrospectively reviewed using immunohistochemical method. All patients were received CHOP chemotherapy over 4 courses. Results P gp was identified in 15 and P26 bcl 2 in 25 cases. The 3 year survival rates for patients with P26 bcl 2(+) and P26 bcl 2(-) were 37.64% and 76.80%, respectively (P<0.005), and for patients with both positive P gp and P26 bcl 2 and both negative were 15.38% and 48.48%,respectively (P=0.038). Conclusions There is direct relationship between the P gp, P26 bcl 2 protein expression and the prognosis in intermediate and high grade non Hodgkin’s lymphoma.更多还原